The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05451433

Enrollment

Registered

2022-07-11

Start date

2022-08-01

Completion date

2022-12-01

Last updated

2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

This study aims to compare the effectiveness of Saccharomyces Boulardii vs Placebo in patient with Irritable Bowel Syndrome

Detailed description

This study aims to compare the effectiveness of Saccharomyces Boulardii vs Placebo in patient with Irritable Bowel Syndrome within timeframe of study 28 days and then will be examined the outcome as the improvement quality of life

Interventions

DRUGSaccharomyces Boulardii 250 MG

Normagut capsule twice a day

DRUGPlacebo

Placebo capsule twice a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

Double blind randomized control trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

s: * 18 years or older * diagnosed with IBS based on ROME IV criteria * agree to be participant by signing inform consent

Exclusion criteria

* patient who does not want to sign the inform consent

Design outcomes

Primary

Measure	Time frame	Description
Clinical improvement quality of life within 29 days	29 days	Measuring quality of life using questionnaire IBS-QOL from 0-100, the higher the score, the better the outcome.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026